AI MARKET SCANNING

Annexon, Inc.

📅 Next Catalyst: Nov 09, 2026 (☀️ Open) 🏛️ NASDAQ 📁 Healthcare 🏭 Biotechnology
AVG HISTORICAL GAP +1.91%
MAX GAP RECORD +7.50%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $ANNX
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Nov 09, 2026 Earnings Release 2026-11-09 (BEFORE OPEN (07:00)) 🔮 UPCOMING 🔒
Aug 17, 2026 Earnings Release 2026-08-17 (AFTER CLOSE)
-1.95%
May 07, 2026 Earnings Release 2026-05-07 (AFTER CLOSE)
+1.72%
Nov 10, 2025 Earnings Release 2025-11-10 (AFTER CLOSE)
-1.01%
Aug 14, 2025 Earnings Release 2025-08-14 (AFTER CLOSE)
+2.94%
May 12, 2025 Earnings Release 2025-05-12 (BEFORE OPEN)
+7.50%
Mar 03, 2025 Earnings Release 2025-03-03 (BEFORE OPEN)
+0.00%
Nov 14, 2024 Earnings Release 2024-11-14 (BEFORE OPEN)
+1.53%

VOLATILITY & GAP BIAS

AVG GAP MOVE 2.5%
Bullish Gaps (8)
Bearish Gaps (2)
Neutral / Flat (3)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $ANNX

EXECUTIONS1 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
2026-10-29 🔒 PRO RADAR ••• x• $•••.•• → $•••.•• 1458m +15.02%
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗